Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 17Multiple Myeloma 15Myelodysplastic Syndromes 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 6Hodgkin Disease 5Hematologic Neoplasms 5Myeloproliferative Disorders 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Anemia, Refractory, with Excess of Blasts 4Recurrence 3Neuroblastoma 3Neoplasm, Residual 3Leukemia, Myelomonocytic, Juvenile 3Graft vs Host Disease 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Precancerous Conditions 2Neoplasms, Plasma Cell 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Leukemia 2Immunoblastic Lymphadenopathy 2

Interventions

daratumumab 4Lenalidomide 3dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Dexamethasone 2Curcumin 2Calcium Dobesilate 2piperine 1isatuximab 1iberdomide 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Leflunomide 1IPH-2101 1Dietary Fiber 1Diet, Mediterranean 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Melphalan × 90 days × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡